Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. - Wikidata - awgldk - TriplyDB

Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.

Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.

http://www.wikidata.org/entity/Q46395433

about

Diagnosis and management of the metabolic syndrome in obesity Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia Type of preexisting lipid therapy predicts LDL-C response to ezetimibe.Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia.Effects of fibrates on C-reactive protein concentrations: a meta-analysis of randomized controlled trials.Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy.Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9 Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV.Low-density lipoprotein size and cardiovascular risk assessment.Fibrates in combination with statins in the management of dyslipidemia.Peroxisome Proliferator-Activated Receptor-α Agonism With Fenofibrate Does Not Suppress Inflammatory Responses to Evoked Endotoxemia.Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview.Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials.Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia?Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy.Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing.Combination therapy in the management of mixed dyslipidaemia.Ezetimibe: cholesterol lowering and beyond.Dietary intake in a randomized-controlled pilot of NOURISH: a parent intervention for overweight children.New options in the treatment of lipid disorders in HIV-infected patients.Dyslipidemia and cardiovascular risk: the importance of early prevention.Fenofibrate: treatment of hyperlipidemia and beyond.Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study.Fenofibrate and metabolic syndrome.Modified intention to treat reporting in randomised controlled trials: systematic review.Fenofibrate in the treatment of dyslipidemia associated with HIV infection.AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types.Safety review of combination drugs for hyperlipidemia.Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism.Relative efficacy of antilipemic agents in non–high-density lipoprotein cholesterol reduction.U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.Diagnosis and management of familial dyslipoproteinemias.Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial.Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multic Micronized fenofibrate: a useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes.Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease.Fenofibrate reduces C-reactive protein levels in hypertriglyceridemic patients with high risks for cardiovascular diseases.

P2860

Q28192856-81667091-E566-40B0-8B7F-99DA531F59DE Q28220294-59CC717D-7BA4-46BB-8F19-28966593FEC8 Q28284661-FD03E8A4-B899-412D-88C9-23994C2D2F2F Q33241121-E6772789-4835-4537-B362-862897637823 Q33577611-247674C0-86BB-4333-AAB4-BE0A128F62B7 Q34068794-415312B4-A9AB-4EB9-9EF3-A2E362EB4B56 Q34079102-AAD0E08E-F2AB-4139-B066-E08C0706EB0E Q34481529-98BE6AAA-8C0E-4CD3-BBD3-41FC33059952 Q35029623-2B666F3D-2FAB-476A-BE19-99077EB365EE Q35771131-C26E87AB-87C8-49FB-8AE3-C4058BD0BFBE Q35906236-815C5A3F-6159-45B2-B2F2-0368DE74226F Q36349994-F26125B8-86F8-45FB-BB42-811DA16DE730 Q36366283-15897FF7-5C05-4F23-99C4-15AE21B512D3 Q36366326-09288C28-9194-4C3D-B804-1F3825CEDC14 Q36653658-E4F2980D-CE28-42BE-BECB-C311C95297C2 Q36835839-C8A9FA98-6637-4C3E-A14D-EB71785946E9 Q36847314-10EF3C5C-19E3-4FAB-82B3-08A7D578331C Q36920620-95A04570-655F-47A0-8A7E-F2E70861F08B Q37019924-4C126BA4-3A1D-49FB-9ECC-A27AA715A188 Q37103948-CC9D47DD-569C-4A45-AE26-4420786A76F0 Q37134467-D26FD9E0-A2E3-4D0C-A11E-A6F0DCC32BF5 Q37207539-66A8E93E-3F4F-4078-83C8-B4664A343969 Q37271807-563B535E-59AF-4958-AE2D-2DF6D3FBA367 Q37311034-74718961-2A45-4268-A175-492C03D67CBF Q37329141-06E2203B-F70C-44B5-BC64-DBB10E932B60 Q37578267-83BA3507-8220-4322-AC38-5364C3ED3BDE Q37612824-A90AA1DE-45D3-4CD2-908B-1B6A46626D99 Q37765079-6CF55C66-6135-4AB8-8064-1B0893217AB7 Q37770249-F6086134-1BE2-4047-B556-BDFFB97BAEB2 Q37851958-20481F44-BAF5-465B-8F06-05496AAD45B7 Q37854747-40CEEE7A-77AB-4E2E-BF0E-69FEB4418EA4 Q37857866-6885001E-95E1-4166-A0D4-30C85F97EF01 Q38007038-229B7601-AB09-45B5-9696-DCAD7A0B123E Q38042090-F89C0304-9EB2-4F50-B093-285E5A9ACCD2 Q38105993-760C3485-6157-4E96-8743-02BDF6BCB4D6 Q38372936-1A82B2AB-4CE6-4BD8-9EDC-B0FF71407B1E Q38382774-A0582179-5A55-44BB-ABB1-CAD15B69147C Q40274682-5EC144D1-29CA-4A88-859D-B898F240BE12 Q41818240-6B3E6A11-EF0D-4BB8-959F-00D6E0A61281 Q42281309-573297DE-B4A0-40B3-97E3-307C9C467D3E

P2860

Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.

http://www.wikidata.org/entity/Q46395433

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Efficacy and safety of the coa ...... ts with mixed hyperlipidaemia.

@en

Efficacy and safety of the coa ...... ts with mixed hyperlipidaemia.

@nl

type

label

Efficacy and safety of the coa ...... ts with mixed hyperlipidaemia.

@en

Efficacy and safety of the coa ...... ts with mixed hyperlipidaemia.

@nl

prefLabel

Efficacy and safety of the coa ...... ts with mixed hyperlipidaemia.

@en

Efficacy and safety of the coa ...... ts with mixed hyperlipidaemia.

@nl

P1433

Q46395433-DE7B1CB5-D6F2-4A25-85AD-9C3F4D4CC37B

P1476

Q46395433-27C17C94-1693-4EDC-90E6-CCB98E29DA88

P2093

Q46395433-3C58F4A5-D181-4AE7-8B53-DA7832C5DF81

Q46395433-41A996B5-4F0F-4382-82DE-6197A2180352

Q46395433-447E3EE9-C8ED-4A65-B221-BD5B9A9B6885

Q46395433-8A204F8D-14BF-434B-9A60-C24813565DCB

Q46395433-8C893FB3-72C8-43FE-9AE9-0DC1130C7731

Q46395433-9664E04C-4093-4601-8E9B-B47D5AC7DFC1

Q46395433-B63C2E82-2FAC-4ABD-814E-71DFA7CDD91A

Q46395433-D261DACD-E9E5-4EDE-B30C-2AE54340F4AB

P2860

Q46395433-0094FC1A-A159-44E7-83E9-F8B2BAE46777

Q46395433-06555B73-3604-4B59-9F1A-0C799EB54A80

Q46395433-097886F5-9380-475E-8420-924FF05EA807

Q46395433-0E1A85D7-A44D-46FF-BF60-7EA11261253E

Q46395433-1FAEAF68-600F-49D1-BD19-520FD99354BF

Q46395433-2C1DD853-A8D8-496E-9748-9D1F7AB6E26A

Q46395433-5584D3D7-213A-405A-8E23-7158F91457C0

Q46395433-5FBFCD9D-66E0-45CA-BE6E-969AE3AEFAC7

Q46395433-90DFFA2C-B761-47C0-99C0-4586C6A63875

Q46395433-91DFF1A8-A849-434C-BE7F-BFE557AD57B7

P304

Q46395433-B49A13A4-E296-4FF3-BFD8-46850E89F204

P31

Q46395433-95B1EF43-AB91-43B1-A75B-8C77C43C1A5B

P356

Q46395433-596D4CD8-82E1-4F01-8B1D-C84BD0778269

P433

Q46395433-6395D8BA-DB21-415E-BDE0-D68DBF04DA0C

P478

Q46395433-DCF95604-9900-46F0-9E6C-E70693DB2858

P577

Q46395433-AE0BD1FE-6E4E-443F-9EDF-3879D0B4C9A8

P5875

Q46395433-904D082F-ACFD-4F6D-90FB-CD5ED4DDA134

P698

Q46395433-CDD34DFD-742C-4F11-9155-9CA8B29F60F7

P921

Q46395433-129D3D52-0B5C-4995-B06A-DDAB2B084C66

Q46395433-8E2CFC17-F11C-4A65-A66D-78902D322AAE

P356

P1433

European Heart Journal

P1476

Efficacy and safety of the coa ...... ts with mixed hyperlipidaemia.

@en

P2093

Barry Gumbiner

http://www.w3.org/2001/XMLSchema#string

Ezetimibe Study Group

http://www.w3.org/2001/XMLSchema#string

Geraldine Macdonell

http://www.w3.org/2001/XMLSchema#string

Inna Perevozskaya

http://www.w3.org/2001/XMLSchema#string

Mason W Freeman

http://www.w3.org/2001/XMLSchema#string

Michael J Davies

http://www.w3.org/2001/XMLSchema#string

Michel Farnier

http://www.w3.org/2001/XMLSchema#string

Yale B Mitchel

http://www.w3.org/2001/XMLSchema#string

P2860

Statin-fibrate combination: therapy for hyperlipidemia: a review

Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia

Statin-fibrate combination therapy.

Effects of fibrates on serum metabolic parameters.

Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks.

The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy.

Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia.

Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy.

Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies.

P304

897-905

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHI231

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2005-03-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7954503

http://www.w3.org/2001/XMLSchema#string

P698

15781429

http://www.w3.org/2001/XMLSchema#string

P921